肝硬化顽固性腹水的治疗

doi:10.3969/j.issn.1004-583X.2021.01.015

摘要/Abstract

摘要：

腹水是肝硬化失代偿期最突出的表现之一,约60%的肝硬化患者会在10年内出现腹水,腹水的顽固性发作使患者2年生存率下降至30%左右。本文就目前国内外研究现状,从新型利尿剂、收缩血管活性药物、大量抽放腹水、经颈静脉肝内门静脉分流术及其利福昔明、非选择性β受体阻滞剂等新的治疗方面对顽固性腹水的治疗进行阐述,旨在为临床医生治疗顽固性腹水提供新思路,以改善患者的生活质量、提高生存率。

中图分类号:

R442.5

佟印妮, 黄艳册, 郑吉敏. 肝硬化顽固性腹水的治疗[J]. 临床荟萃, 2021, 36(1): 70-74.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.01.015

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I1/70

参考文献 35

[1]	徐小元, 丁惠国, 李文刚, 等. 肝硬化腹水及相关并发症的诊疗指南(2017, 北京)[J]. 中华胃肠内镜电子杂志, 2018,5(1):1-17.
[2]	Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clin Gastroenterol Hepatol, 2006,4(11):1385-1394. doi: 10.1016/j.cgh.2006.08.007 URL
[3]	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018,69(2):406-460. doi: 10.1016/j.jhep.2018.03.024 URL
[4]	丁惠国. 从《肝硬化腹水及相关并发症的诊疗指南》探讨肝硬化顽固性腹水诊治"路线图"[J]. 临床肝胆病杂志, 2018,34(1):31-34.
[5]	Josiassen RC, Curtis J, Filmyer DM, et al. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders[J]. Expert Opin Pharmacother, 2010,11(4):637-648. doi: 10.1517/14656561003610656 pmid: 20163274
[6]	Sakaida I, Nakajima K, Okita K, et al. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan[J]. J Gastroenterol, 2015,50(10):1047-1053. doi: 10.1007/s00535-015-1052-5 URL
[7]	Hiramine Y, Uto H, Mawatari S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites[J]. Hepatol Res, 2019,49(7):765-777.
[8]	Wang S, Zhang X, Han T, et al. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia[J]. BMC Gastroenterol, 2018,18(1):137. doi: 10.1186/s12876-018-0857-0 URL
[9]	邢枫, 李爽, 张建军, 等. 特利加压素对顽固性肝硬化腹水的治疗作用与效应特点观察[J]. 中华肝脏病杂志, 2019,27(12):982-988.
[10]	Wong F, Pappas SC, Boyer TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome[J]. Clin Gastroenterol Hepatol, 2017,15(2):266-272. doi: 10.1016/j.cgh.2016.07.016 URL
[11]	Singh V, Dhungana SP, Singh B, et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study[J]. J Hepatol, 2012,56(2):348-354. doi: 10.1016/j.jhep.2011.04.027 URL
[12]	Guo TT, Yang Y, Song Y, et al. Effects of midodrine in patients with ascites due to cirrhosis: systematic review and meta-analysis[J]. J Dig Dis, 2016,17(1):11-19. doi: 10.1111/1751-2980.12304 URL
[13]	Lin CH, Shih FY, Ma MH, et al. Should bleeding tendency deter abdominal paracentesis?[J]. Dig Liver Dis, 2005,37(12):946-951. doi: 10.1016/j.dld.2005.07.009 URL
[14]	Alessandria C, Elia C, Mezzabotta L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study[J]. Dig Liver Dis, 2011,43(11):881-886. doi: 10.1016/j.dld.2011.06.001 pmid: 21741331
[15]	Di Pascoli M, Fasolato S, Piano S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites[J]. Liver Int, 2019,39(1):98-105. doi: 10.1111/liv.13968 pmid: WOS:000454415500012
[16]	Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites[J]. Hepatology, 2004,40(3):629-635. doi: 10.1002/(ISSN)1527-3350 URL
[17]	Rossle M. TIPS: 25 years later[J]. J Hepatol, 2013,59(5):1081-1093. doi: 10.1016/j.jhep.2013.06.014 URL
[18]	中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南[J]. 中华肝脏病杂志, 2019,27(8):582-593.
[19]	Bucsics T, Hoffman S, Grunberger J, et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis[J]. Liver Int, 2018,38(6):1036-1044. doi: 10.1111/liv.2018.38.issue-6 URL
[20]	林志鹏, 赵剑波, 陈斯良. 采用Viatorr覆膜支架建立经颈静脉肝内门体静脉分流术的中期疗效分析[J]. 中华肝脏病杂志, 2019,27(6):440-444.
[21]	蒋明明, 徐浩, 张庆桥, 等. 经颈静脉肝内门体分流术在门静脉高压并发顽固性腹水及静脉曲张出血患者个体化治疗中的初步应用[J]. 中华医学杂志, 2019,99(47):3737-3740.
[22]	Bureau C, Adebayo D, Chalret DRM, et al. Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study[J]. J Hepatol, 2017,67(5):940-949. doi: 10.1016/j.jhep.2017.06.010 URL
[23]	Wong F, Bendel E, Sniderman K, et al. Improvement in quality of life and decrease in large-volume paracentesis requirements with the automated low-flow ascites pump[J]. Liver Transpl, 2020,26(5):651-661. doi: 10.1002/lt.v26.5 URL
[24]	Hanada R, Yokomichi N, Kato C, et al. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study[J]. Support Care Cancer, 2018,26(5):1489-1497. doi: 10.1007/s00520-017-3980-5 pmid: 29168037
[25]	Yoshizawa M, Nakatsuji Y. Improvement of major problems in the cell-free and concentrated ascites reinfusion therapy system horizontal line constructing of cell-free and concentrated ascites reinfusion therapy system using external pressure for filtration[J]. Ther Apher Dial, 2019,23(3):233-236. doi: 10.1111/tap.2019.23.issue-3 URL
[26]	陈照林, 董静, 宋海燕, 等. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者临床研究[J]. 实用肝脏病杂志, 2020,23(4):556-559.
[27]	王新亭, 张传雷, 陈晓琦, 等. 腹水超滤浓缩腹腔回输联合周期性白蛋白输注治疗顽固性腹水的效果观察[J]. 中国临床新医学, 2018,11(6):554-558.
[28]	Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J]. Clin Gastroenterol Hepatol, 2012,10(7):815-818. doi: 10.1016/j.cgh.2012.02.025 URL
[29]	Lv XY, Ding HG, Zheng JF, et al. Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study[J]. World J Gastroenterol, 2020,26(2):199-218. doi: 10.3748/wjg.v26.i2.199 URL
[30]	Singh V, Singh A, Singh B, et al. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study[J]. Am J Gastroenterol, 2013,108(4):560-567. doi: 10.1038/ajg.2013.9 URL
[31]	Aday AW, Mayo MJ, Elliott A, et al. The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension and ascites[J]. Am J Med Sci, 2016,351(2):169-176. doi: 10.1016/j.amjms.2015.11.018 URL
[32]	Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J]. Hepatology, 2010,52(3):1017-1022. doi: 10.1002/hep.23775 URL
[33]	Krag A, Wiest R, Albillos A, et al. The window hypojournal: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease[J]. Gut, 2012,61(7):967-969. doi: 10.1136/gutjnl-2011-301348 URL
[34]	Homler H. Beta-blocker use in refractory ascites[J]. Mayo Clin Proc, 2019,94(11):2364.
[35]	王宏彬, 汪小平. 小剂量奥曲肽用于肝硬化顽固性腹水疗效观察[J]. 山东医药, 2011,51(19):59-60.

肝硬化顽固性腹水的治疗

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 35

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	金鑫, 吴金玲, 尹丽丽. 持续性植物状态促醒机制及治疗研究进展[J]. 临床荟萃, 2024, 39(2): 172-176.
[3]	王琦, 陈宏. 维生素D在支气管哮喘和慢性阻塞性肺疾病治疗中的应用进展[J]. 临床荟萃, 2024, 39(1): 88-91.
[4]	崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74.
[5]	邹子良, 余海, 王迪, 褚泰运, 李驹, 钱宝堂. 冠状动脉慢性完全闭塞病变介入治疗研究现状[J]. 临床荟萃, 2024, 39(1): 80-83.
[6]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[7]	王鑫, 张展, 刘铎, 谢萍. 铁缺乏与肺动脉高压相关性的研究进展[J]. 临床荟萃, 2023, 38(9): 838-844.
[8]	陈聪水, 李园, 陈淑芳. 重视儿童胆源性胰腺炎的中西医诊治(附1例分析)[J]. 临床荟萃, 2023, 38(8): 726-730.
[9]	武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.
[10]	侯有玲, 李奕, 关红玉, 罗红霞. 目标导向液体治疗在脑肿瘤切除术中应用效果的meta分析[J]. 临床荟萃, 2023, 38(8): 686-693.
[11]	王玥, 陈辉, 岑奕, 张哲, 张欣, 李宗锡, 陈珍珍, 贾彤彤, 章美玲. 超声引导下侧入路颈脊神经后支三氧联合注射松解治疗颈脊神经后支源性慢性颈肩痛[J]. 临床荟萃, 2023, 38(8): 714-718.
[12]	张会, 丁东瑞, 金天然. 新型冠状病毒SARS-CoV-2的相关研究——过去与未来[J]. 临床荟萃, 2023, 38(7): 638-646.
[13]	郭文惠, 雷皓月, 潘友卓, 张琦. 质膜膜泡关联蛋白的生物学功能研究进展[J]. 临床荟萃, 2023, 38(7): 647-653.
[14]	陈瑾, 吕鸿雁, 刘晗, 刘建宁, 卢佳配, 张金巧. 靶向BCMA的嵌合抗原受体T细胞治疗三重难治性多发性骨髓瘤的研究进展[J]. 临床荟萃, 2023, 38(7): 654-658.
[15]	杨小雄, 杨帆, 魏小果. 肠-微生物群-肝轴与代谢相关脂肪性肝病的研究进展[J]. 临床荟萃, 2023, 38(6): 559-563.